Ceftaroline Fosamil: A Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureus

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 743-765

  Poon, Henry ^a   Chang, Mei H ^a   Fung, Horatio B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ceftaroline; Cephalosporin; Community acquired pneumonia; Methicillin resistant Staphylococcus aureus; Skin and skin structure infections

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; ASPARTATE AMINOTRANSFERASE; AVIBACTAM; AZTREONAM; CEFEPIME; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CLOXACILLIN; CREATININE; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PLACEBO; TAZOBACTAM; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ABNORMAL URINE COMPOSITION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL MENINGITIS; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BURN INFECTION; CELLULITIS; COLONY FORMING UNIT; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; ENDOCARDITIS; FIRST PASS EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; IC 50; INSOMNIA; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OSTEOMYELITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; PLASMA CLEARANCE; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABSCESS; SKIN BRUISING; SKIN STRUCTURE INFECTION; STAPHYLOCOCCUS; SURGICAL INFECTION; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE COLOR; URINE DISCOLORATION; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VOMITING; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEPHALOSPORINS; HALF-LIFE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS;

EID: 84859625801     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.025     Document Type: Review

References (92)

1. Spellberg B., Powers J.H., Brass E.P., et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004, 28:1279-1286.
2. Klevens R.M., Edwards J.R., Tenover F.C., et al. Changes in the epidemiology of Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006, 42:389-391.
3. Moran G.J., Amii R.N., Abrahamian F.M., Talan D.A. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005, 11:928-930.
4. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
5. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the Unites States. JAMA 2007, 298:1763-1771.
6. Richter S.S., Heilmann K.P., Dohrn C.L., et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009, 48:e23-e33.
7. Skoff T.H., Farley M.M., Petit S., et al. Increasing burden of invasive Group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009, 49:85-92.
8. McCaig L.F., McDonald L.C., Mandal S., Jernigan D.B. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006, 12:1715-1723.
9. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
10. Kochanek K.D., Xu J.Q., Murphy S.L., et al. Deaths: preliminary data for 2009. National Vital Statistics Reports 2011, 59:41-69. National Center for Health Statistics, Hyattsville, Md.
11. Niederman M.S. Community-acquired pneumonia: management controversies, part 1; practical recommendations from the latest guidelines. J Respir Dis 2002, 23:10-17.
12. Kollef M.H., Shorr A., Tabak Y.P., et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
13. Moore C.L., Hingwe A., Donabedian S.M., et al. Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and healthcare-associated infections. Int J Antimicrob Agents 2009, 34:148-155.
14. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
15. Lim D., Strynadka N.C. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 2002, 9:870-876.
16. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
17. Hiramatsu K., Hanaki H., Ino T., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40:135-136.
18. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001, 1:147-155.
19. Tenover F.C., Biddle J.W., Lancaster M.V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001, 7:327-332.
20. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002, 51:902. Centers for Disease Control and Prevention.
21. Wang G., Hindler J.F., Ward K.W., Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886.
22. NDA 200327. NDA approval US Department of Health and Human Services, Accessed April 30, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/200327s000ltr.pdf.
23. Teflaro [package insert] 2011, Forest Laboratories, Inc, St Louis, Mo, Accessed April 30, 2011. http://www.frx.com/pi/teflaro_pi.pdf.
24. Sader H.S., Fritsche T.R., Kaniga K., et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005, 49:3501-3512.
25. Saravolatz L., Pawlak J., Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010, 54:3027-3030.
26. Ishikawa T., Matsunaga N., Tawada H., et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003, 11:2427-2437.
27. Villegas-Estrada A., Lee M., Hesek D., et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc 2008, 130:9212-9213.
28. Moisan H., Pruneau M., Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010, 65:713-716.
29. Karlowsky J.A., Adam H.J., Decorby M.R., et al. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients attending Canadian hospitals in 2009. Antimicrob Agents Chemother 2011, 55:2837-2846.
30. Ge Y., Biek D., Talbot G.H., Sahm D.F. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 52:3398-3407.
31. Morrissey I., Ge Y., Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009, 33:515-519.
32. Brown S.D., Traczewski M.M. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009, 53:1271-1274.
33. Jones R.N., Mendes R.E., Sader H.S. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010, 65:iv17-iv31.
34. Sader H.S., Fritsche T.R., Jones R.N. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:1153-1155.
35. Zhanel G.G., Rossnagel E., Nichol K., et al. Ceftaroline pharmacodynamics activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. J Antimicrob Chemother 2011, 66:1301-1305.
36. Jacobs M.R., Good C.E., Windau A.R., et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010, 54:2716-2719.
37. McGee L., Biek D., Ge Y., et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009, 53:552-556.
38. Vidaillac C., Leonard S.N., Sader H.S., et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53:2360-2366.
39. Mushtaq S., Livermore D.M. AmpC induction by ceftaroline. J Antimicrob Chemother 2010, 65:586-588.
40. Snydman D.R., Jacobus N.V., McDermott L.A. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 2011, 55:421-425.
41. Citron D.M., Tyrrell K.L., Merriam C.V., Goldstein E.J. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010, 54:1627-1632.
42. Fung H.B., Kuczynski S., Finch D.A., Ramos L. Current issues in gram-negative resistance: extended-spectrum beta-lactamases and inducible beta-lactamases. J Pharm Pract 2001, 14:6-17.
43. Jacqueline C, Caillon J, Miegeville AF, et al. Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit. Abstract presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Abstract A-1938.
44. Cottagnoud P, Acosta F, Biek D, et al. Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant Streptococcus pneumoniae in an experimental rabbit meningitis model. Abstract presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 13-14, 2010; Boston, Mass. Abstract B-702.
45. Ge Y, Redman R, Floren L, et al. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. Abstract presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Abstract A-1936.
46. Ge Y, Redman R, Floren L, et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. Abstract presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Abstract A-1937.
47. Van Wart SA, Forrest A, Bhavnani SM, et al. Population pharmacokinetics of ceftaroline in healthy and renally impaired subjects. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif. Abstract A1-004.
48. Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M). Abstract presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Abstract A-1935.
49. Ge Y, Thye D, Liao S, Talbot GH. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI). Abstract presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Abstract A-1939.
50. Riccobene T, Fang E, Thye D. An open-label pharmacokinetic (PK), safety, and tolerability study of single intravenous (IV) doses of ceftaroline (CPT) in subjects with normal renal function or severe renal impairment. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif. Abstract A1-003.
51. Riccobene T., Jakate A., Rank D., Thye D. An open-label pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis. Clin Microbiol Infect 2009, 15(Suppl s4):S407.
52. Clinical pharmacology and biopharmaceutics review(s), Teflaro (ceftaroline fosamil) injection drug approval package (Application number: 200327) Bethesda, Md: Center for Drug Evaluation and Research, US Food and Drug Administration, Accessed April 30, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200327Orig1s000ClinPharmR.pdf.
53. Riccobene T, Jakate A, Rank D, Thye D. Open-label pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in healthy elderly and healthy young adult subjects. Abstract presented at: 2009 Midyear Clinical Meeting of the American Society of Health-System Pharmacists; December 6-10, 2009; Las Vegas, NV. Abstract 3-161.
54. Riccobene T, Fang E, Thye D. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; October 25-28, 2008; Washington, DC. Abstract A-1888.
55. Efficacy and safety of ceftaroline versus linezolid in subjects with complicated skin and skin structure infections ClinicalTrials.gov, Accessed April 30, 2011. http://clinicaltrials.gov/ct2/show/NCT00633152?term=ceftaroline&rank=3.
56. Jones R.N., Fritsche T.R., Ge Y., et al. Evaluation of PPI-090M (T91825)., a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005, 56:1047-1052.
57. Vidaillac C., Leonard S.N., Rybak M.J. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009, 53(11):4712-4717.
58. Iizawa Y., Nagai J., Ishikawa T., et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004, 10:146-156.
59. Sader HS, Moet G, Fritsche TR, Jones RN. Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline (PPI-0903M) compared to ceftriaxone against Streptococcus pneumoniae. Abstract presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Abstract E-0121.
60. Jacqueline C., Caillon J., Le Mabecque V., et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007, 51:3397-3400.
61. Pankuch G.A., Appelbaum P.C. Postantibiotic effect of ceftaroline against gram-positive organisms. Antimicrob Agents Chemother 2009, 53:4537-4539.
62. Andes D., Craig W.A. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006, 50:1376-1383.
63. Vidaillac C., Leonard S.N., Rybak M.J. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents 2010, 35:527-530.
64. Bonnefoy A., Dupuis-Hamelin C., Steier V., et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother 2004, 54:410-417.
65. Bowker K, Noel A, Elliott H, et al. Comparison of the antibacterial effects of two dosing regimens of ceftaroline in combination with NXL104 against Enterobacteriaceae. Abstract presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA. Abstract A1-1377.
66. Craig WA, Andes DR. Pharmacodynamics (PD) of ceftaroline (CPT) fosamil plus 1:1 and 2:1 ratios of NXL104 (NXL) against Enterobacteriaceae (ENT) containing ESBLs and carbapenemases (KPCs) in neutropenic mouse thighs. Abstract presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA. Abstract A1-1387.
67. Levasseur P, Girard A-M, Williams G, et al. In vivo antibacterial efficacy of ceftaroline (CPT) combined with the beta-lactamase inhibitor NXL104 in a murine septicemia model. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif. Abstract B-1339a.
68. Wiskirchen D.E., Crandon J.L., Furtado G.H., et al. In vivo efficacy of a human-simulated regimen of ceftaroline fosamil combined with NXL104 (CXL) against ESBL- and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011, 55:3220-3225.
69. Credito K, Ednie LM, Appelbaum PC. Comparative time-kill analysis of ceftaroline (CPT) with and without NXL104 (NXL) against anaerobes. Abstract presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA. Abstract A1-1396.
70. Low D.E., File T.M., Eckburg P.B., et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66:iii33-iii44.
71. Panagiotidis G., Bäckström T., Asker-Hagelberg C., et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010, 54:1811-1814.
72. Clark C, Kosowska-Shick K, McGhee P, Appelbaum P. Multistep resistance development studies of ceftaroline (CPT) with Streptococcus pneumoniae, Streptococcus pyogenes, staphylococci, and enterococci. Abstract presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston MA. Abstract E-813.
73. Clark C, Kosowska-Shick K, McGhee P, Appelbaum P. Multistep resistance development studies of ceftaroline (CPT) with Haemophilus influenzae and Moraxella catarrhalis. Abstract presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA. Abstract E-814.
74. Croisier-Bertin D., Piroth L., Charles P.E., et al. Ceftaroline vs ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia model. Clin Microbiol Infect 2009, 15(Suppl s4):S81.
75. Cottagnoud P., Stucki A., Accosta F., et al. Ceftaroline is superior to cefepime against a Klebsiella pneumoniae strain an experimental rabbit meningitis model. Clin Microbiol Infect 2010, 16(Suppl s2):S4565.
76. Jacqueline C., Amador G., Batard E., et al. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2011, 66:863-866.
77. Jacqueline C., Caillon J., Batard E., et al. Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model. J Antimicrob Chemother 2010, 65:2264-2265.
78. Jacqueline C., Amador G., Caillon J., et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010, 65:1749-1752.
79. Talbot G.H., Thye D., Das A., Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007, 51:3612-3616.
80. Corey G.R., Wilcox M.H., Talbot G.H., et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010, 65:iv41-iv51.
81. Wilcox M.H., Corey G.R., Talbot G.H., et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010, 65:iv53-iv 65.
82. File T.M., Low D.E., Eckburg P.B., et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66:iii19-iii32.
83. Corey G.R., Wilcox M., Talbot G.H., et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010, 51:641-650.
84. File T.M., Low D.E., Eckburg P.B., et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010, 51:1395-1405.
85. Medical review(s), Teflaro (ceftaroline fosamil) injection drug approval package (Application number: 200327). Center for Drug Evaluation and Research, US Food and Drug Administration Accessed April 30, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200327Orig1s000MedR.pdf.
86. A single-centre, randomised, double-blind, placebo-controlled, four way crossover phase I study to investigate the effect on QT/QTc interval of ceftazidime NXL 104 or ceftaroline fosamil NXL104, compared with placebo, using moxifloxacin (Avelox®) as a positive control, in healthy male volunteers ClinicalTrials.gov, Accessed April 30, 2011. http://clinicaltrials.gov/ct2/show/NCT01290900?term=ceftaroline&rank=4.
87. Comparative study of coadministered ceftaroline fosamil and NXL 104 vs intravenous doripenem in adult subjects with complicated urinary tract infections ClinicalTrials.gov, Accessed April 30, 2011. http://clinicaltrials.gov/ct2/show/NCT01281462?term=ceftaroline&rank=5.
88. Critchley I.A., Eckburg P.B., Jandourek A., et al. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 2011, 66:iii45-iii51.
89. Corrado M.L. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010, 65:iv67-iv 71.
90. Rank D.R., Friedland H.D., Laudano J.B. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011, 66:iii53-iii59.
91. 2011 Drug Topics Red Book 2011, Thomson Medical Economics, Montvale, NJ.
92. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.